A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma
Tu, YanyangNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationZhang, P., J. Gao, X. Wang, W. Wen, H. Yang, Y. Tian, N. Liu, et al. 2017. “A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma.” Oncology Letters 14 (2): 2053-2058. doi:10.3892/ol.2017.6397. http://dx.doi.org/10.3892/ol.2017.6397.
AbstractMalignant glioma, the most common form of primary brain tumor, is associated with substantial morbidity and mortality, owing to the lack of response shown by patients to conventional therapies. Additional therapeutic targets and effective treatment options for these patients are therefore required. In the present study, a possible association of thioredoxin-interacting protein (TXNIP) with malignant glioma was evaluated. Initially, semi-quantitative and quantitative analysis of the expression levels of TXNIP in clinical specimens of primary glioma was performed via immunohistochemistry (IHC) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), respectively, and expression levels were further correlated to the overall survival time of the patients. The proliferative, migratory and invasive properties of the glioblastoma U251 cell line, engineered to downregulate TXNIP by lentiviral transfection of a specific short hairpin RNA, were evaluated by means of in vitro assays. Consequently, IHC and RT-qPCR analysis revealed a negative association between the expression level of TXNIP and the histopathological grade of the tumor. Higher TXNIP expression level was associated with extended patient survival time. In vitro analysis revealed increased growth, migration and invasion in U251 cells with downregulated TXNIP expression compared with their non-transfected counterparts. These findings strongly indicate that TXNIP functions as a tumor suppressor in malignant glioma cells and underscore its potential as a novel therapeutic target and prognostic indicator of the condition.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34375171
- HMS Scholarly Articles